Lu177-DOTA-octreotate therapy on neuroendocrine tumour management: A case report and literature review

Favourable outcomes of peptide receptor radiotherapy of neuroendocrine tumors have been reported during the last years. This case report refers to a patient with a non-functional neuroendocrine carcinoma of pancreas with liver metastases and abdominal lymph nodes involvement. He underwent fractionated treatment with 4 cycles of Lu 177 -DOTA-octreoate (7.400MBq) after the failure of treatment with chemotherapy regiments. We conclude that fractionated therapy with Lu 177 -DOTA-octreotate should be considered a treatment option in the management of patients for symptomatic improvement in inoperable or metastasized neuroendocrine tumors, and for patients with large tumors and high somatostatin receptor expression.